finanznachrichten.de
Cure8 news brief
Why This Matters
This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.
Patients and clinicians tracking new therapies or complications like intestinal fibrosis may find the upcoming ECCO presentations relevant.
Who Should Pay Attention
Clinicians and researchers in IBD, adult patients and caregivers following investigational IBD therapies, and patients concerned about fibrosis/stricture complications.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
The company is sharing expanded clinical and preclinical data for obefazimod — an investigational therapy — at a major IBD conference.
The oral presentation highlights preclinical anti-fibrotic findings (in cell and mouse models) and the rest of the abstracts include pooled Phase 3 trial data (ABTECT-1/2) on symptoms, biomarkers, and tolerability in ulcerative colitis.
These presentations describe research findings and help the scientific community evaluate obefazimod’s potential, but they do not by themselves change clinical care. If you follow IBD research or clinical trials, these abstracts are a source of new data to watch as peer-reviewed publication or regulatory updates follow.
For more detail, see the company’s ECCO 2026 program listings and the original Abivax announcement for the full abstract titles and presenters.
Keep In Mind
These are conference abstract presentations and preclinical/model findings; they are not definitive clinical evidence or regulatory decisions. Phase 3 trial subgroup analyses and preclinical anti-fibrotic results require peer review and replication before changing practice. The source is a company press release summarizing its ECCO abstracts.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationfinanznachrichten.de
Indexed viaBing News
Source typeResearch news
PublishedFeb 17, 2025, 11:19 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
These are multi‑year clinical results for a newly approved IL‑23p19 inhibitor (mirikizumab) showing sustained clinical and endoscopic benefit for many patients with moderate‑to‑severe Crohn’s disease, including some who...
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...